Navigation Links
Pacific Biosciences Raises $100 Million to Fund Commercial Product Development
Date:7/14/2008

MENLO PARK, Calif., July 14 /PRNewswire/ -- Pacific Biosciences announced today that it has secured $100 million in a Series E private equity financing round. The proceeds will be used to fund the commercial development of the company's innovative single-molecule, real-time (SMRT(TM)) DNA sequencing platform.

The transaction was co-led by Deerfield Capital Management and Intel Capital, Intel Corporation's global investment organization. Other new investors included: Morgan Stanley, Redmile Group, T. Rowe Price, and a large financial institution. All previous investors participated in the financing, including: Mohr Davidow Ventures, Kleiner Perkins Caufield and Byers, Alloy Ventures, Maverick Capital, AllianceBernstein, DAG Ventures, and Teachers' Private Capital.

"With the backdrop of a difficult market, we believe that this substantial investment by our current and new investors validates the promise of our SMRT(TM) technology to change the field of DNA sequencing and spark a true revolution in medical care," said Hugh Martin, chairman and chief executive officer of Pacific Biosciences. "These funds from a combination of key institutional investors as well as Intel, a world class provider of semiconductor technology, will enable us to surge forward with an aggressive development program and stay on track to commercialize our technology in 2010."

Pacific Bioscience's SMRT(TM) technology enables, for the first time, the observation of natural DNA synthesis by a DNA polymerase as it occurs. The technology is distinguished by its long reads, fast run times, and high quality sequence data with less effort and cost compared to other available sequencing technologies. The company believes these advances will lead to a transformation in the field of DNA sequencing that will enable sequencing of individual genomes as part of routine medical care.

About Pacific Biosciences

Pacific Biosciences is a private company based in Menlo Park, California. The company was founded in 2004 with the goal of developing a transformative SMRT(TM) (single molecule real time) DNA sequencing platform that will become the new gold standard for genetic analysis. The SMRT(TM) technology is built upon two key innovations that overcome major challenges facing the field of DNA sequencing. The first is the SMRT(TM) chip, which enables observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a high signal-to-noise ratio. The second are phospholinked nucleotides, which produce a completely natural DNA strand through fast, accurate, and processive DNA synthesis. The company has received an Advanced Sequencing Technology Award grant from the NHGRI (National Human Genome Research Institute) to develop the $1,000 genome. More information is available at http://www.pacificbiosciences.com.


'/>"/>
SOURCE Pacific Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PacificGMP to Merge With Pacific Biopharma Group and Create Innovative US-Compliant cGMP Contract Biomanufacturing Facility in China
2. Pacific Biosciences Acquires Single Molecule Sequencing Technology from LI-COR Biosciences
3. Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
4. BioMed Realty Trust Announces 140,000 Square Foot Lease With DayStar Technologies at Pacific Research Center
5. PacifiCare Capitulates to Latest Patient Revolt
6. Neptune Technologies expands into medicinal markets in Asia Pacific
7. Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region
8. Verenium Corporation to Present at the Pacific Growth Equities 2007 Clean Technology & Industrial Growth Conference
9. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
10. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
11. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Founder of ... board-certified in surgery and surgery of the hand by the National Board of ... to going above and beyond in his pursuit of providing the most comprehensive, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven ... Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 for ... designation granted by the FDA. , Spinocerebellar ataxia is a rare, debilitating ...
(Date:5/23/2016)... ... 2016 , ... The need for blood donations in South Texas and across the nation is ... & Tissue Center, blood donations are on the decline. In fact, donations across the country ... percent in South Texas in the last four years alone. , There is no substitute ...
(Date:5/23/2016)... ... May 23, 2016 , ... RoviSys, a ... based in Aurora, Ohio, has broken ground on a new building in Holly ... Park area, this new location solidifies a commitment to business in the region. ...
Breaking Biology Technology:
(Date:3/21/2016)... March 22, 2016 Unique ... passcodes for superior security   ... provider of secure digital communications services, today announced it ... and offer enterprise customers, particularly those in the Financial ... and voice authentication within a mobile app, alongside, and ...
(Date:3/14/2016)... , March 14, 2016 NXTD ) ... mobile commerce market, announces the airing of a new series ... the week of March 21 st .  The commercials will ... its popular Squawk on the Street show. --> ... the growing mobile commerce market, announces the airing of a ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
Breaking Biology News(10 mins):